GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Gross Profit

Cyteir Therapeutics (Cyteir Therapeutics) Gross Profit : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics Gross Profit?

Cyteir Therapeutics's gross profit for the three months ended in Sep. 2023 was $0.00 Mil. Cyteir Therapeutics's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Cyteir Therapeutics's gross profit for the three months ended in Sep. 2023 was $0.00 Mil. Cyteir Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Cyteir Therapeutics's Gross Margin % for the quarter that ended in Sep. 2023 was N/A%.

Cyteir Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage


Cyteir Therapeutics Gross Profit Historical Data

The historical data trend for Cyteir Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyteir Therapeutics Gross Profit Chart

Cyteir Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Gross Profit
- - - -

Cyteir Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cyteir Therapeutics's Gross Profit

For the Biotechnology subindustry, Cyteir Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyteir Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Cyteir Therapeutics's Gross Profit falls into.



Cyteir Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Cyteir Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Cyteir Therapeutics's Gross Profit for the quarter that ended in Sep. 2023 is calculated as

Gross Profit (Q: Sep. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Cyteir Therapeutics's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Cyteir Therapeutics  (OTCPK:CYTT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Cyteir Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage


Cyteir Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Executives
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness officer: General Counsel C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey director C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong director 69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven 10 percent owner BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421